Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Biochemical Research Methods
Seunghyun Wang, Doheon Lee
Summary: In this study, two prognostic subgroups (BPS-LumA and WPS-LumA) of luminal-A breast cancer were identified using deep autoencoders and gene expressions. The prognostic difference between the two subgroups was validated using external datasets. The study also found that latent features were superior to gene expression profiles in discovering the prognostic subgroups.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Medicine, Research & Experimental
Sewon Hwang, Soojun Park, Jee Hyun Kim, Sang-Beom Bang, Hyeon-Ji Kim, Na-Lee Ka, Yoonae Ko, Seung-Su Kim, Ga Young Lim, Seunghee Lee, Young Kee Shin, So Yeon Park, Sanghee Kim, Mi-Ock Lee
Summary: This study aimed to identify lipid metabolic perturbations in tamoxifen-resistant breast cancer (BC) and investigate the role of HMGCS2 in BC growth. Comprehensive metabolomics and transcriptomics analysis were conducted. The upregulation of HMGCS2 was verified in tamoxifen-resistant BC cells and clinical samples. A HMGCS2 inhibitor was discovered and its effect on tumor growth was studied.
Article
Biochemistry & Molecular Biology
Zhi Xu, Xiumei Wang, Wenbo Sun, Fan Xu, Hengyuan Kou, Weizi Hu, Yanyan Zhang, Qin Jiang, Jinhai Tang, Yong Xu
Summary: This study reveals the contribution of RelB-upregulated GPX4 in inhibiting ferroptosis to tamoxifen resistance in breast cancer.
Article
Oncology
Dawoon Jeong, Juyeon Ham, Hyeon Woo Kim, Heejoo Kim, Hwee Won Ji, Sung Hwan Yun, Jae Eun Parks, Keun Seok Lee, Heein Jo, Jai Hong Hang, So-Youn Jung, Seeyoun Lee, Eun Sook Lee, Han-Sung Kang, Sun Jung Kim
Summary: This study identified that the hypermethylation and downregulation of ELOVL2 gene in TamR breast cancer patients could lead to drug resistance, while its restoration significantly increased Tam sensitivity. The findings also revealed the potential role of ELOVL2 in regulating key genes involved in drug resistance pathways.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Tredan, Muriel Le Romancer
Summary: Endocrine therapies targeting estrogen signaling have improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, resistance to treatment remains a challenge. This study identifies nuclear PRMT5 expression as a predictive marker of sensitivity to tamoxifen in breast cancer patients, and reveals the mechanism of tamoxifen stimulating ERα methylation by PRMT5. This biomarker could be used to enhance response to tamoxifen in ERα-positive breast tumors.
EMBO MOLECULAR MEDICINE
(2023)
Article
Oncology
Belinda J. Petri, Kellianne M. Piell, Gordon C. South Whitt, Ali E. Wilt, Claire C. Poulton, Norman L. Lehman, Brian F. Clem, Matthew A. Nystoriak, Marcin Wysoczynski, Carolyn M. Klinge
Summary: The RNA binding protein and m6A reader HNRNPA2B1 is overexpressed in breast tumors compared to normal tissue. Overexpression of A2B1 leads to tamoxifen and fulvestrant resistance, while knockdown of A2B1 restores endocrine sensitivity. Targeting A2B1 could be a potential therapeutic strategy to overcome acquired endocrine resistance in breast cancer.
Article
Pharmacology & Pharmacy
Cheng Huang, Liangping Su, Yitian Chen, Sangqing Wu, Ruipu Sun, Qiuping Xu, Xiaoyi Qiu, Ciqiu Yang, Xiangzhan Kong, Hongquan Qin, Xinbao Zhao, Xue Jiang, Kun Wang, Yinghua Zhu, Ping-Pui Wong
Summary: Dysregulated sphingolipid metabolism contributes to ER+ breast cancer progression and therapeutic response. This study established sphingolipid metabolic enzyme CERK as a regulator of TAMR in breast cancer, demonstrating its role in tamoxifen resistance and tumor growth. Mechanistically, high CERK expression inhibits tamoxifen-induced sphingolipid ceramide accumulation, leading to tamoxifen resistance in TAMR cells. This work provides valuable insight into the regulation of sphingolipid metabolism and identifies a potential therapeutic target for tamoxifen resistance in breast cancer.
PHARMACOLOGICAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Anette M. Skjervold, Marit Valla, Borgny Ytterhus, Anna Bofin
Summary: This study aimed to assess the association between PAK1 gene copy number and proliferation status, molecular subtype, and prognosis in breast cancer. The results showed that PAK1 copy number increase is associated with high proliferation and high histological grade, but not with prognosis. PAK1 copy number increase is most frequent in the HER2 type and Luminal B (HER2(-)) subtype and is associated with CCND1 copy number increase.
Article
Radiology, Nuclear Medicine & Medical Imaging
Thi Xuan Mai Tran, Soyeoun Kim, Huiyeon Song, Eunhye Lee, Boyoung Park
Summary: Breast density changes over time are associated with breast cancer risk in both premenopausal and postmenopausal women. Continuous increase in breast density increases the future risk of breast cancer, while continuous decrease in breast density is associated with a lower risk.
Article
Cell Biology
Yu Cheon Kim, Clara Yuri Kim, Ji Hoon Oh, Myoung Hee Kim
Summary: This study suggests that NR4A1 could be a potential therapeutic target to overcome tamoxifen resistance in ER-positive breast cancer patients. High NR4A1 expression correlated with increased survival rates following tamoxifen treatment, and experiments showed that NR4A1 restored sensitivity to tamoxifen by regulating various cellular processes. Further analysis revealed that NR4A1 enhanced responsiveness to tamoxifen by suppressing ERK signaling, indicating its potential as a targeted therapy for tamoxifen-resistant breast cancer.
Article
Oncology
Javier A. Menendez, Adriana Papadimitropoulou, Travis Vander Steen, Elisabet Cuyas, Bharvi P. Oza-Gajera, Sara Verdura, Ingrid Espinoza, Luciano Vellon, Inderjit Mehmi, Ruth Lupu
Summary: The study highlights the critical role of fatty acid synthase (FASN) in HER2-driven tamoxifen resistance and suggests that FASN inhibition could be a novel therapeutic approach to restore tamoxifen sensitivity in endocrine-resistant breast cancer.urther research using next-generation FASN inhibitors may be therapeutically relevant in countering resistance to tamoxifen in FASN-overexpressing ER+/HER2+ breast carcinomas.
Article
Medicine, Research & Experimental
Ming Li Jin, Liu Yang, Kwang Won Jeong
Summary: This study reveals the critical role of the SETD1A-SOX2 axis in tamoxifen resistance in breast cancer cells. Overexpression of SETD1A leads to increased resistance to tamoxifen, and high levels of SETD1A and SOX2 are significantly associated with a low survival rate in breast cancer patients.
Article
Chemistry, Medicinal
Min Chang Choi, Sang Kyum Kim, Young Jae Choi, Yong June Choi, Suntae Kim, Kyung Hwan Jegal, Sung Chul Lim, Keon Wook Kang
Summary: This study reveals that tamoxifen-resistant breast cancer cells rely on glycolysis for energy and are more tolerant to lactate-rich environments. Targeting lactate recycling mediated by MCT1 and LDHB may be a promising therapeutic strategy for tamoxifen-resistant breast cancer.
ARCHIVES OF PHARMACAL RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Mengqi Sun, Shu Zhao, Yuchen Duan, Yumeng Ma, Yicheng Wang, Hongfei Ji, Qingyuan Zhang
Summary: The study revealed that in tamoxifen-resistant breast cancer cells, GLUT1 expression and autophagy flux were increased, and knockdown of GLUT1 could promote sensitivity to tamoxifen. Additionally, inhibiting autophagy could resensitize tamoxifen-resistant cells to tamoxifen.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Kaichun Li, Mingzhen Ying, Dan Feng, Jie Du, Shiyu Chen, Bing Dan, Cuihua Wang, Yajie Wang
BIOMEDICINE & PHARMACOTHERAPY
(2016)
Article
Oncology
Kaichun Li, Mingzhen Ying, Dan Feng, Yan Chen, Jingwen Wang, Yajie Wang
Review
Gastroenterology & Hepatology
Kaichun Li, Jin Li
GASTROENTEROLOGY RESEARCH AND PRACTICE
(2016)
Review
Oncology
Bing Dan, Jie Luo, Kaichun Li, Shiyu Chen
ONCOLOGY RESEARCH AND TREATMENT
(2018)
Article
Biochemistry & Molecular Biology
Kaichun Li, Qiaoyun Wang, Yanyan Lu, Xiaorong Pan, Long Liu, Shiyu Cheng, Bingxiang Wu, Zongchang Song, Wei Gao
Summary: This study confirmed the important role of Brachyury in breast cancer, showing that patients with high Brachyury expression have lower survival rates and are associated with ER expression. The decision tree model performed the best in predicting the survival status of patients with breast cancer.
BIOSCIENCE REPORTS
(2021)
Article
Pharmacology & Pharmacy
Siyue Zhang, Fangyuan Xie, Kaichun Li, He Zhang, You Yin, Yuan Yu, Guangzhao Lu, Shihao Zhang, Yan Wei, Ke Xu, Yan Wu, Hong Jin, Lan Xiao, Leilei Bao, Can Xu, Yulin Li, Ying Lu, Jie Gao
Summary: This study successfully initiated antitumor immunotherapy by inhibiting TAMs M2 polarization using PEG-AuNPs. It was found that PEG-AuNPs induced lysosome dysfunction and autophagic flux inhibition, leading to reduced M2 polarization of TAMs. These findings provide new insights into harnessing the intrinsic immunomodulation capacity of nanomaterials for effective cancer treatment.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Biophysics
Kaichun Li, Dong Zhou, Hengqing Cui, Guoyan Mo, Yu Liu, Kaikai Zheng, Zheng Zhou, Jian Li, Ping Dai, Jing Sun, Yuhong Zhang, Jie Gao
Summary: This study developed nanoparticles for cancer treatment that can gradually release drugs in the tumor environment, achieving deep tumor penetration and efficient tumor cell therapy. The nanoparticles have good stability and biocompatibility, making them a promising and practical approach for anticancer therapy.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2022)
Article
Clinical Neurology
Weibo Yu, Xiaobing Jiang, Haiyan Zhang, Zhensong Yao, Yuanming Zhong, Fubo Tang, Daozhang Cai
Summary: A risk prediction model for RCAV was developed and validated, and a modified puncture technique was proposed for RCAV prevention. The study demonstrated the accuracy and clinical utility of the prediction model and the efficacy of the modified puncture technique.
JOURNAL OF NEUROSURGERY-SPINE
(2023)
Article
Pharmacology & Pharmacy
Wenyan Yu, Zhuning Wang, Ping Dai, Jing Sun, Jian Li, Wei Han, Kaichun Li
Summary: In this study, the researchers found that resveratrol (RES) can inhibit breast cancer metastasis through the suppression of NETs formation. In a mouse model, RES significantly hindered breast cancer metastasis and increased immune cell infiltration. Mechanistically, RES suppressed NETs formation by inhibiting SIRT1 activity.
JOURNAL OF DRUG TARGETING
(2023)
Article
Oncology
Wenyan Yu, Changli Ding, Kaichun Li
Summary: This case report summarizes the treatment of a 57-year-old male patient with CXPA of the left parotid gland, harboring HER2 amplification with poor prognosis. The overall survival of the patient has been > 3.5 years. The application and outcome of an immune checkpoint inhibitor and targeted therapy combination regimens in the treatment of CXPA carcinoma are discussed.
Article
Oncology
Kaichun Li, Liying Pang, Xiaorong Pan, Shaonan Fan, Xinxin Wang, Qiaoyun Wang, Ping Dai, Wei Gao, Jie Gao
Summary: Encapsulation of Sal in GE11 modified PLGA/TPGS nanoparticles shows improved therapy efficacy and lower systemic side effects, promising as a strategy for enhancing therapeutic effect against EGFR highly expressed breast cancer.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2021)
Review
Medicine, Research & Experimental
Weizhuo Lu, Zhiwu Chen, Jiyue Wen
Summary: Ischemic stroke is a common and serious disease, and neuroinflammation plays a crucial role in its progression. Microglia, astrocytes, and infiltrating immune cells are involved in the complicated neuroinflammation cascade, releasing different molecules that affect inflammation. Flavonoids, plant-specific compounds, have shown protective effects against cerebral ischemia injury by modulating the inflammatory responses.
BIOMEDICINE & PHARMACOTHERAPY
(2024)
